Patents by Inventor Dirk Eulberg

Dirk Eulberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SDF-1 Binding Nucleic Acids
    Publication number: 20210139909
    Abstract: The present invention is related to a nucleic acid molecule, preferably binding to SDF-I, selected from the group comprising type A nucleic acid molecules, type B nucleic acid molecules, type C nucleic acid molecules and nucleic acid molecules having a nucleic acid sequence according to any of SEQ. ID. No. 142, SEQ. ID. No. 143 and SEQ. ID. No. 144.
    Type: Application
    Filed: November 9, 2020
    Publication date: May 13, 2021
    Applicant: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • MCP-1 binding nucleic acids
    Patent number: 10273480
    Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 87 to 115.
    Type: Grant
    Filed: June 6, 2017
    Date of Patent: April 30, 2019
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
  • SDF-1 binding nucleic acids and the use thereof in cancer treatment
    Patent number: 10093934
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Grant
    Filed: July 3, 2016
    Date of Patent: October 9, 2018
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
  • SDF-1 Binding Nucleic Acids
    Publication number: 20180163207
    Abstract: The present invention is related to an L nucleic acid that binds to an SDF-1.
    Type: Application
    Filed: November 20, 2017
    Publication date: June 14, 2018
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • SDF-1 binding nucleic acids and the use thereof
    Patent number: 9988636
    Abstract: The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: June 5, 2018
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • MCP-1 Binding Nucleic Acids
    Publication number: 20180066265
    Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group comprising type 1A nucleic acids, type 1B nucleic acids, type 2 nucleic acids, type 3 nucleic acids, type 4 nucleic acids and nucleic acids having a nucleic acid sequence according to any of SEQ.ID.No. 87 to 115.
    Type: Application
    Filed: June 6, 2017
    Publication date: March 8, 2018
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
  • SDF-1 binding nucleic acids
    Patent number: 9822369
    Abstract: The present invention is related to an L nucleic acid that binds to an SDF-1.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: November 21, 2017
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • Means and Methods for the Treatment of Nephropathy
    Publication number: 20170233737
    Abstract: The present invention is related to an antagonist of CCL2 for use in a method for the treatment and/or prevention of a disease, wherein the method comprises administering the antagonist to a subject, wherein the subject is suffering from proteinuria.
    Type: Application
    Filed: November 4, 2014
    Publication date: August 17, 2017
    Applicant: NOXXON PHARMA AG
    Inventors: Dirk Eulberg, Matthias Baumann
  • MCP-1 binding nucleic acids
    Patent number: 9670491
    Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3 nucleic acids, Type 4 nucleic acids and nucleic acids comprising SEQ ID NOs:87-115
    Type: Grant
    Filed: April 6, 2014
    Date of Patent: June 6, 2017
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
  • SDF-1 binding nucleic acids and the use thereof in cancer treatment
    Publication number: 20160355821
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Application
    Filed: July 3, 2016
    Publication date: December 8, 2016
    Applicant: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
  • SDF-1 Binding Nucleic Acids and the Use Thereof
    Publication number: 20160326531
    Abstract: The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.
    Type: Application
    Filed: July 26, 2016
    Publication date: November 10, 2016
    Applicant: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • MCP-1 Binding Nucleic Acids
    Publication number: 20160208262
    Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3 nucleic acids, Type 4 nucleic acids and nucleic acids comprising SEQ ID NOs:87-115
    Type: Application
    Filed: April 6, 2014
    Publication date: July 21, 2016
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
  • SDF-1 binding nucleic acids and the use thereof in cancer treatment
    Patent number: 9387221
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: July 12, 2016
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
  • SDF-1 binding nucleic acids and the use thereof in cancer treatment
    Publication number: 20160095875
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to SDF-1, preferably capable of inhibiting SDF-1, whereby the nucleic acid molecule is for use in a method for the treatment and/or prevention of a disease or disorder, for use in a method for the treatment of a subject suffering from a disease or disorder or being at risk of developing a disease or disorder as an adjunct therapy, or for use as a medicament for the treatment and/or prevention of a disease or disorder, whereby the disease or disorder is cancer.
    Type: Application
    Filed: November 20, 2015
    Publication date: April 7, 2016
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse, Dirk Zboralski
  • SDF-1 Binding Nucleic Acids
    Publication number: 20150232853
    Abstract: The present invention is related to an L nucleic acid that binds to an SDF-1.
    Type: Application
    Filed: May 6, 2015
    Publication date: August 20, 2015
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • Use of spiegelmers
    Patent number: 9074214
    Abstract: The present invention relates to the use of a L-nucleic acid as intracellularly active agent.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: July 7, 2015
    Assignee: NOXXON Pharma AG
    Inventors: Axel Vater, Christian Maasch, Sven Klussmann, Werner Purschke, Dirk Eulberg, Florian Jarosch, Klaus Buchner
  • MCP-1 Binding Nucleic Acids and Use Thereof
    Publication number: 20150141496
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to MCP-I, whereby the nucleic acid molecule is for use as a medicament for the treatment and/or prevention of a chronic disease or chronic disorder, preferably selected from the group consisting of chronic respiratory disease, chronic kidney disease and systemic lupus erythematosus.
    Type: Application
    Filed: May 15, 2014
    Publication date: May 21, 2015
    Applicant: NOXXON PHARMA AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
  • SDF-1 binding nucleic acids
    Patent number: 9035038
    Abstract: The present invention is related to an L nucleic acid that binds to an SDF-1.
    Type: Grant
    Filed: October 13, 2012
    Date of Patent: May 19, 2015
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • SDF-1 Binding Nucleic Acids and the Use Thereof
    Publication number: 20140370034
    Abstract: The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.
    Type: Application
    Filed: July 6, 2014
    Publication date: December 18, 2014
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse
  • SDF-1 binding nucleic acids and the use thereof
    Patent number: 8772257
    Abstract: The present invention is related to a nucleic acid molecule binding to SDF-1, whereby the nucleic acid molecule influences migration of cells.
    Type: Grant
    Filed: August 6, 2008
    Date of Patent: July 8, 2014
    Assignee: NOXXON Pharma AG
    Inventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch, Nicole Dinse